Qualigen Therapeutics Announces $4.5 Million Private Placement of Series A-3 Convertible Preferred Stock
Qualigen Therapeutics (NASDAQ:QLGN), a life sciences company focused on cancer treatments, has secured $4.5 million in private placement funding through the sale of Series A-3 Preferred Stock. The company sold 4,500 shares at $1,000 per share to institutional and accredited investors.
The Series A-3 Preferred Stock is convertible into 1,607,143 common shares at an initial conversion price of $2.80 per share. Univest, LLC served as the exclusive placement agent, and the proceeds will be used for working capital purposes. The company has committed to filing a registration statement with the SEC within 45 days for the resale of the underlying common shares.
Qualigen Therapeutics (NASDAQ:QLGN), un'azienda nel settore delle scienze della vita focalizzata sui trattamenti contro il cancro, ha ottenuto 4,5 milioni di dollari tramite un collocamento privato mediante la vendita di azioni privilegiate di Serie A-3. La societ脿 ha venduto 4.500 azioni a 1.000 dollari ciascuna a investitori istituzionali e accreditati.
Le azioni privilegiate di Serie A-3 sono convertibili in 1.607.143 azioni ordinarie a un prezzo di conversione iniziale di 2,80 dollari per azione. Univest, LLC ha agito come agente esclusivo per il collocamento, e i proventi saranno utilizzati per il capitale circolante. L'azienda si 猫 impegnata a presentare una dichiarazione di registrazione alla SEC entro 45 giorni per la rivendita delle azioni ordinarie sottostanti.
Qualigen Therapeutics (NASDAQ:QLGN), una empresa de ciencias de la vida enfocada en tratamientos contra el c谩ncer, ha asegurado 4,5 millones de d贸lares en financiamiento mediante colocaci贸n privada a trav茅s de la venta de acciones preferentes Serie A-3. La compa帽铆a vendi贸 4,500 acciones a 1,000 d贸lares por acci贸n a inversores institucionales y acreditados.
Las acciones preferentes Serie A-3 son convertibles en 1,607,143 acciones ordinarias a un precio de conversi贸n inicial de 2.80 d贸lares por acci贸n. Univest, LLC actu贸 como agente exclusivo de colocaci贸n, y los fondos se utilizar谩n para capital de trabajo. La empresa se ha comprometido a presentar una declaraci贸n de registro ante la SEC dentro de 45 d铆as para la reventa de las acciones ordinarias subyacentes.
Qualigen Therapeutics (NASDAQ:QLGN)電� 鞎� 旃橂鞐� 欷戩爯鞚� 霊� 靸濍獏瓿柬暀 旮办梾鞙茧, 鞁滊Μ歃� A-3 鞖办劆欤茧ゼ 韱淀暅 450毵� 雼煬鞚� 靷 韼�霐�鞚� 頇曤炒頄堨姷雼堧嫟. 須岇偓電� 旮瓣磤 氚� 瓿奠澑 韴瀽鞛愲摛鞐愱矊 欤茧嫻 1,000雼煬鞐� 4,500欤�毳� 韺愲Г頄堨姷雼堧嫟.
鞁滊Μ歃� A-3 鞖办劆欤茧姅 齑堦赴 鞝勴櫂臧� 欤茧嫻 2.80雼煬搿� 1,607,143欤检潣 氤错喌欤茧 鞝勴櫂 臧�電�頃╇媹雼�. Univest, LLC臧� 雼弲 氚办爼 雽�頄夓偓搿� 頇滊彊頄堨溂氅�, 鞛愱笀鞚� 鞖挫爠鞛愲掣 鞖╇弰搿� 靷毄霅� 鞓堨爼鞛呺媹雼�. 須岇偓電� 旮办磮 氤错喌欤� 鞛寪毵るゼ 鞙勴暣 45鞚� 鞚措偞鞐� SEC鞐� 霌彪 靹滊毳� 鞝滌稖頃� 瓴冹潉 鞎届啀頄堨姷雼堧嫟.
Qualigen Therapeutics (NASDAQ:QLGN), une soci茅t茅 des sciences de la vie sp茅cialis茅e dans les traitements contre le cancer, a obtenu 4,5 millions de dollars de financement priv茅 via la vente d'actions privil茅gi茅es de s茅rie A-3. La soci茅t茅 a vendu 4 500 actions 脿 1 000 dollars chacune 脿 des investisseurs institutionnels et accr茅dit茅s.
Les actions privil茅gi茅es de s茅rie A-3 sont convertibles en 1 607 143 actions ordinaires 脿 un prix de conversion initial de 2,80 dollars par action. Univest, LLC a agi en tant qu'agent de placement exclusif, et les fonds seront utilis茅s pour le fonds de roulement. La soci茅t茅 s'est engag茅e 脿 d茅poser une d茅claration d'enregistrement aupr猫s de la SEC dans les 45 jours pour la revente des actions ordinaires sous-jacentes.
Qualigen Therapeutics (NASDAQ:QLGN), ein Life-Sciences-Unternehmen mit Schwerpunkt auf Krebsbehandlungen, hat 4,5 Millionen US-Dollar durch eine Privatplatzierung durch den Verkauf von Series A-3 Vorzugsaktien erhalten. Das Unternehmen verkaufte 4.500 Aktien zu je 1.000 US-Dollar an institutionelle und akkreditierte Investoren.
Die Series A-3 Vorzugsaktien sind in 1.607.143 Stammaktien wandelbar zu einem anf盲nglichen Wandlungspreis von 2,80 US-Dollar pro Aktie. Univest, LLC fungierte als exklusiver Platzierungsagent, und die Erl枚se werden f眉r das Betriebskapital verwendet. Das Unternehmen hat sich verpflichtet, innerhalb von 45 Tagen eine Registrierungsanmeldung bei der SEC f眉r den Weiterverkauf der zugrunde liegenden Stammaktien einzureichen.
- Secured $4.5 million in new capital funding
- Participation from institutional and accredited investors showing confidence in the company
- Potential dilution for existing shareholders upon conversion of preferred stock
- Shares issued at private placement suggesting possible challenges with public market fundraising
Insights
Qualigen secured $4.5M through preferred stock offering to fund cancer treatment R&D, strengthening short-term capital position without immediate dilution.
Qualigen Therapeutics has secured
This capital raise appears primarily aimed at strengthening Qualigen's working capital position to advance its cancer treatment platforms. As a clinical-stage biotech focused on developing treatments for adult and pediatric cancers with orphan drug designation potential, maintaining adequate funding is critical for advancing through costly clinical development phases.
The structure of the deal - using convertible preferred stock rather than direct equity or debt - provides Qualigen with immediate capital without immediate dilution to current shareholders. The
Without knowing Qualigen's current cash burn rate, it's difficult to determine exactly how much runway this
Carlsbad, CA, July 28, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("Qualigen" or the "Company"), a life sciences company focused on developing platform treatments for adult and pediatric cancers with the potential for orphan drug designations, today announced that it has entered into definitive securities purchase agreements with several institutional and accredited investors for the sale of its Series A-3 Preferred Stock. The private placement closed on July 28, 2025. The Company issued and sold an aggregate of 4,500 shares of Series A-3 Preferred Stock, with a stated value of
Univest, LLC acted as the exclusive placement agent for the offering.
The Company intends to use the net proceeds from the sale of the Series A-3 Preferred Stock for working capital purposes.
The shares of Series A-3 Preferred Stock were offered and issued in a private placement under Section 4(a)(2) and/or Rule 506(b) of Regulation D under the Securities Act of 1933 and have not been registered under the Securities Act or applicable state securities laws. Accordingly, the shares of Series A-3 Preferred Stock and the underlying shares of common stock may not be offered or sold in the United States unless registration with the Securities and Exchange Commission (the "SEC") or an applicable exemption from such registration requirements.
The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock underlying the Series A-3 Preferred Stock within 45 days after the closing date.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About Qualigen Therapeutics, Inc.
Qualigen Therapeutics, Inc. (NASDAQ: QLGN) is a clinical-stage biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases. The Company鈥檚 pipeline includes QN-302, a selective G-quadruplex inhibitor targeting various tumor types including pancreatic cancer; QN-247, a nucleolin-targeting compound for hematologic malignancies; and a family of small-molecule RAS oncogene protein-protein interaction inhibitors. Each of these programs is designed to address areas of high unmet medical need, with the potential for orphan drug designation. Qualigen is committed to advancing its therapeutic pipeline to improve patient outcomes and create long-term value for shareholders.
For more information about Qualigen Therapeutics, Inc., please visit .
Forward-Looking Statements
This press release contains 鈥渇orward-looking statements鈥� within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on current expectations, estimates, assumptions, and projections about future events and involve inherent risks and uncertainties. These forward-looking statements include, but are not limited to, statements the filing of a resale registration statement, and the Company鈥檚 future business plans and strategies.
Words such as 鈥渁nticipates,鈥� 鈥渆xpects,鈥� 鈥渋ntends,鈥� 鈥減lans,鈥� 鈥渂elieves,鈥� 鈥渟eeks,鈥� 鈥渆stimates,鈥� 鈥渕ay,鈥� 鈥渨ill,鈥� 鈥渃ould,鈥� 鈥渨ould,鈥� 鈥渟hould,鈥� 鈥渃ontinues,鈥� and similar expressions are intended to identify such forward-looking statements. Actual results could differ materially from those projected due to a number of factors, including risks related to the Company鈥檚 ability to successfully develop and commercialize its product candidates, regulatory developments, market conditions, the Company鈥檚 ability to maintain compliance with Nasdaq listing requirements, and other risks described in the Company鈥檚 filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.
The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact: Investor Relations
.
Source: Qualigen Therapeutics, Inc.
FAQ
What is the size of Qualigen Therapeutics' (QLGN) recent private placement?
What is the conversion price for QLGN's Series A-3 Preferred Stock?
How will Qualigen Therapeutics use the proceeds from the Series A-3 Preferred Stock offering?
When will QLGN file the registration statement for the underlying common shares?
Who acted as the placement agent for QLGN's private placement?
